|
| Status |
Public on Apr 18, 2018 |
| Title |
MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to ROS augmenting agents |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Through a small scale metabolic-modulator screening, we have identified dimethyl fumarate (DMF), a FDA approved drug for multiple sclerosis, which suppresses neuroblastoma cell growth in vitro and in vivo. Mechanistically, DMF suppresses neuroblastoma cell growth through inducing ROS and subsequently suppressing MYCN expression.
|
| |
|
| Overall design |
Biological duplicate samples were treated with 100uM of DMF for 6 and 12 hours.
|
| |
|
| Contributor(s) |
Yang J, Wang R |
| Citation(s) |
29445162 |
| Submission date |
Apr 26, 2017 |
| Last update date |
Jul 25, 2021 |
| Contact name |
JUN YANG |
| E-mail(s) |
jun.yang2@stjude.org
|
| Organization name |
St Jude Children's Research Hospital
|
| Department |
Surgery
|
| Street address |
262 Danny Thomas Place
|
| City |
Memphis |
| State/province |
TN |
| ZIP/Postal code |
38105 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16686 |
[HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version] |
|
| Samples (6)
|
|
| Relations |
| BioProject |
PRJNA384369 |
Less...
More...